Open Access


Read more
image01

Online Manuscript Submission


Read more
image01

Submitted Manuscript Trail


Read more
image01

Online Payment


Read more
image01

Online Subscription


Read more
image01

Email Alert



Read more
image01

Original Research Article | OPEN ACCESS

Integrative analysis of inhibitor of DNA-binding expression and prognosis in non-small cell lung cancer

Denggang Fu1, Biyu Zhang2, Jinghui Sun1, Jueping Feng3, Xin Wang4

1College of Medicine, Medical University of South Carolina, Charleston, SC, 29425, USA; 2Key Laboratory of Green Chemical Engineering Process of Ministry of Education, Hubei Key Laboratory of Novel Reactor and Green Chemical Technology, School of Chemical Engineering and Pharmacy, Wuhan Institute of Technology, Wuhan 430079, China; 3Wuhan Fourth Hospital, Wuhan, Hubei 430033, China; 4School of Medicine, Jiujiang University, Jiujiang, Jiangxi 332005, China.

For correspondence:-  Xin Wang   Email: wangxin0072@126.com   Tel:+86 138 7920 8703

Received: 26 January 2024        Revised: 13 September 2024        Accepted: 13 September 2024        Published: 29 October 2024

Citation: Fu D, Zhang B, Sun J, Feng J, Wang X. Integrative analysis of inhibitor of DNA-binding expression and prognosis in non-small cell lung cancer. Trop J Pharm Res 2024; 23(10):1605-1616 doi: 10.4314/tjpr.v23i10.3

© 2024 The authors.
This is an Open Access article that uses a funding model which does not charge readers or their institutions for access and distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/4.0) and the Budapest Open Access Initiative (http://www.budapestopenaccessinitiative.org/read), which permit unrestricted use, distribution, and reproduction in any medium, provided the original work is properly credited..

Abstract

Purpose: To investigate the expression and prognosis of inhibitor of DNA-binding (ID) protein family in non-small cell lung cancer (NSCLC). Methods: The mRNA expression and prognostic relevance of ID family using Oncomine, UALCAN, Kaplan-Meier plot, and The Cancer Genome Atlas (TCGA) databases were compiled and analyzed. Also, associations between individual IDs' mRNA expression and clinicopathological features in NSCLC patients were identified using unpaired t-test. Results: There was significantly higher expression of each ID in normal cells compared to NSCLC tissues, including adenocarcinoma (AC) and squamous cell carcinoma (SCC; p < 0.05). High ID1 mRNA expression correlated significantly with worse overall survival in NSCLC, AC, and SCC cases (p < 0.05). Also, increased ID4 mRNA expression predicted significantly better overall survival in NSCLC and AC cases, but not in SCC (p < 0.05). Conclusion: Inhibitor of DNA-binding 1 mRNA predicts poorer survival, whereas ID4 mRNA suggests better survival, particularly in AC. ID2 and ID3 mRNA levels lack significant associations with overall survival, suggesting targeting IDs might represent potential therapeutics for NSCLC. There is the need for validation of these outcomes and mechanistic investigations.

Keywords: Inhibitor of DNA-binding, Non-small cell lung cancer, Gene expression, Prognosis

Impact Factor
Thompson Reuters (ISI): 0.523 (2021)
H-5 index (Google Scholar): 39 (2021)

Article Tools

Share this article with



Article status: Free
Fulltext in PDF
Similar articles in Google
Similar article in this Journal:

Archives

2024; 23: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10
2023; 22: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2022; 21: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2021; 20: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2020; 19: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2019; 18: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2018; 17: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2017; 16: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2016; 15: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2015; 14: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2014; 13: 
1,   2,   3,   4,   5,   6,   7,   8,   9,   10,   11,   12
2013; 12: 
1,   2,   3,   4,   5,   6
2012; 11: 
1,   2,   3,   4,   5,   6
2011; 10: 
1,   2,   3,   4,   5,   6
2010; 9: 
1,   2,   3,   4,   5,   6
2009; 8: 
1,   2,   3,   4,   5,   6
2008; 7: 
1,   2,   3,   4
2007; 6: 
1,   2,   3,   4
2006; 5: 
1,   2
2005; 4: 
1,   2
2004; 3: 
1
2003; 2: 
1,   2
2002; 1: 
1,   2

News Updates